COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
23/04/2026
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need. The trial demonstrated a statistically [...]
Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call
23/04/2026
ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14 [...]
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
23/04/2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
23/04/2026
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing [...]
ENA Respiratory Appoints Melissa Faris to Board
23/04/2026
MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Orion Group Interim report January–March 2026
23/04/2026
ORION CORPORATION INTERIM REPORT 1–3/2026 23 APRIL 2026 at 12:00 EEST Orion Group Interim report January–March 2026 January–March 2026 Highlights Net sales totalled EUR 417.7 (January–March 2025: 354.6) million [...]
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
23/04/2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in- [...]
Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé
23/04/2026
Nomme la professeure Susana Banerjee, éminente oncologue du Royal Marsden, en tant que chercheuse principale CAMBRIDGE, Royaume-Uni et MONTRÉAL, 23 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société biotechnologique [...]
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
23/04/2026
Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three [...]
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA
23/04/2026
T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC 1 et BNPA 2 des activités de 1,88 euro Les ventes des nouveaux lancements Pharma [...]
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
23/04/2026
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno [...]
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
23/04/2026
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN [...]
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
23/04/2026
Croissance du chiffre d’affaires total de 22,6 % à taux de change constant 1 , ou 17,0 % en données publiées, portée par les trois aires thérapeutiques, avec une accélération de la dynamique du portefeuille hors [...]
Zelluna ASA – Annual General Meeting held on April 23, 2026
23/04/2026
Oslo, April 23, 2026: Zelluna ASA held its annual general meeting on April 23, 2026. All matters on the agenda were approved. The minutes from the meeting are enclosed and are also available on the company’s website. [...]
Santhera Appoints Orlando Oliveira as Chief Executive Officer
23/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of [...]
Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement
23/04/2026
CHICAGO, 23 avr. 2026 (GLOBE NEWSWIRE) -- L’une des questions les plus fondamentales de la biologie est de comprendre comment un seul œuf fécondé produit la diversité des types cellulaires constituant le corps — des [...]
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
23/04/2026
-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene [...]
Press Release: Q1 2026: double-digit sales and business EPS growth
23/04/2026
Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER 1 and business earnings per share (EPS) 2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 [...]
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
23/04/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]

Pages